Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Silence Therapeutics

    NASDAQ: SLN · Real-Time Price · USD
    5.34
    0.28 (5.53%)
    At close: Jun 17, 2025, 3:16 PM

    Silence Therapeutics Statistics

    Share Statistics

    Silence Therapeutics has 47.23M shares outstanding. The number of shares has increased by 204.18% in one year.

    Shares Outstanding

    n/a
    		 47.23M

    Shares Change (YoY)

    n/a
    		 204.18%

    Shares Change (QoQ)

    n/a
    		 200.06%

    Owned by Institutions (%)

    n/a
    		 17.7%

    Shares Floating

    n/a
    		 37.61M

    Failed to Deliver (FTD) Shares

    n/a
    		 328

    FTD / Avg. Volume

    n/a
    		 0.15%

    Short Selling Information

    The latest short interest is 1.05M, so 2.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.05M

    Short % of Shares Out

    n/a
    		 2.23%

    Short % of Float

    n/a
    		 2.82%

    Short Ratio (days to cover)

    n/a
    		 6.52

    Valuation Ratios

    The PE ratio is -7.17 and the forward PE ratio is -9.71. Silence Therapeutics's PEG ratio is 0.44.

    PE Ratio

    n/a
    		 -7.17

    Forward PE

    n/a
    		 -9.71

    PS Ratio

    n/a
    		 7.51

    Forward PS

    n/a
    		 1

    PB Ratio

    n/a
    		 2.42

    P/FCF Ratio

    n/a
    		 -4.79

    PEG Ratio

    n/a
    		 0.44
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Silence Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 11.14, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 11.14

    Quick Ratio

    n/a
    		 11.14

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $372,913.79

    Profits Per Employee

    n/a
    		 $-390,594.83

    Employee Count

    n/a
    		 116

    Asset Turnover

    n/a
    		 0.21

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 845K

    Effective Tax Rate

    n/a
    		 -1.9%

    Stock Price Statistics

    The stock price has increased by -73.11% in the last 52 weeks. The beta is 1.41, so Silence Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.41

    52-Week Price Change

    n/a
    		 -73.11%

    50-Day Moving Average

    n/a
    		 4.12

    200-Day Moving Average

    n/a
    		 8.79

    Relative Strength Index (RSI)

    n/a
    		 52.02

    Average Volume (20 Days)

    n/a
    		 222,357

    Income Statement

    In the last 12 months, Silence Therapeutics had revenue of 43.26M and earned -45.31M in profits. Earnings per share was -0.98.

    Revenue

    n/a
    		 43.26M

    Gross Profit

    n/a
    		 31.45M

    Operating Income

    n/a
    		 -63.32M

    Net Income

    n/a
    		 -45.31M

    EBITDA

    n/a
    		 -48.99M

    EBIT

    n/a
    		 -49.58M

    Earnings Per Share (EPS)

    n/a
    		 -0.98
    Full Income Statement

    Balance Sheet

    The company has 121.33M in cash and 117K in debt, giving a net cash position of 121.21M.

    Cash & Cash Equivalents

    n/a
    		 121.33M

    Total Debt

    n/a
    		 117K

    Net Cash

    n/a
    		 121.21M

    Retained Earnings

    n/a
    		 -474.04M

    Total Assets

    n/a
    		 185.3M

    Working Capital

    n/a
    		 189.05M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -67.64M and capital expenditures -211K, giving a free cash flow of -67.85M.

    Operating Cash Flow

    n/a
    		 -67.64M

    Capital Expenditures

    n/a
    		 -211K

    Free Cash Flow

    n/a
    		 -67.85M

    FCF Per Share

    n/a
    		 -0.48
    Full Cash Flow Statement

    Margins

    Gross margin is 72.7%, with operating and profit margins of -146.38% and -104.74%.

    Gross Margin

    n/a
    		 72.7%

    Operating Margin

    n/a
    		 -146.38%

    Pretax Margin

    n/a
    		 -102.79%

    Profit Margin

    n/a
    		 -104.74%

    EBITDA Margin

    n/a
    		 -113.25%

    EBIT Margin

    n/a
    		 -146.38%

    FCF Margin

    n/a
    		 -156.85%

    Dividends & Yields

    SLN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SLN is $25, which is 389.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $25

    Price Target Difference

    n/a
    		 389.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.77

    Piotroski F-Score

    n/a
    		 0

    Add to Watchlist